Replies to post #6600 on Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[BigGreen101]

The note concerning uplisting is interesting. I now predict that we might have uplisting around March 19th. This will give NasDaq 30 days to review the 10Q and decide.

This is just a guess on my account and is only based on a rough extrapolation as to when other Chinese companies actually made it to NasDaq after their second report. We have been waiting since Oct, when JGBO submitted their application, to have conformation.

Thus, I feel that if we are not uplisted in two months, JGBO has some major flaw that NasDaq can see and we cannot.

Enjoy your evening.

[996]

Good find Ericteg: to me this seems like a positive thing:
1. I would think the cash problem will be resolved by the 35th of Feb and
2. Uplisting should be done by the 15th of April

We can also see that parts of the loans have been converted.
"Note 19- Subsequent event
In January 2010, the Company issued 311,250 shares of its common stock in connection with the conversion of $2,490,000 of May 2008
Convertible Debentures"

"In September 2009, the Company issued 62,500 shares of its common stock in connection with the conversion of $500,000 of convertible debt.
In October 2009, the Company issued 462,500 shares of its common stock in connection with the conversion of $3,700,000 of convertible debt.
In November 2009, the Company issued 62,500 shares of its common stock in connection with the conversion of $500,000 of convertible debt.
In December 2009, the Company issued 62,500 shares of its common stock in connection with the conversion of $500,000 of convertible debt.
"
So in total 12+M shares are outstanding already.

I admit I am feeling dissapointed by this filing. Things should have looked better. But the coming months until April/May will be very decisive !!